Monday marked a major milestone for Pliant Therapeutics, as the company launched its public offering of $175 million worth of common stock. These funds will be used to further the progress of its clinical and preclinical programs, helping to bring innovative treatments to patients in need.
On January 21st, Pliant released the interim findings from its Phase IIa INTEGRIS-IPF trial, which proved to be highly promising. In the wake of these results, the company has now announced a public offering.
At 12 weeks of treatment, Bexotegrast, a promising investigational therapeutic for idiopathic pulmonary fibrosis (IPF), proved to be generally well-tolerated and had a positive pharmacokinetic profile when administered at the highest dose of 320 mg. Its results indicate that it could be a promising treatment option for IPF in the future.
No severe drug-related adverse events were found in INTEGRIS-IPF, with all side effects being of mild or moderate intensity. Thankfully, no major reactions to the medication were reported.
The efficacy of bexotegrast was tested and the results showed that a dose of 320 mg. proved to be highly effective in improving forced vital capacity from baseline values. Not only that, but there was also a powerful effect on profibrotic biomarkers and Quantitative Lung Fibrosis imaging results. These findings suggest that bexotegrast could be a promising treatment option for those suffering from lung-related conditions.
Bernard Coulie, M.D., Ph.D., President and CEO of Pliant, expressed his excitement over the data from the 320 mg. arm of INTEGRIS-IPF, which exceeded all his expectations.
In July 2022, the company announced promising early results from their study of bexotegrast, revealing that even lower doses of the medication ranging from 40 to 160 mg were well-tolerated. These findings offer further hope that the medication can help to improve the quality of life for many patients.
Today’s data is an extraordinary breakthrough in IPF clinical drug development, with no prior evidence to compare it to. Dr. Coulie is thrilled with the results and eager to continue research in this area.
Eric Lefebvre, M.D., chief medical officer at Pliant, announced on Monday that participants in the 320 mg. arm of INTEGIRS-IPF will receive bexotegrast for a minimum of 24 weeks, providing them with a unique opportunity to benefit from this treatment.
Pliant is eagerly awaiting the results of the final data, set to arrive in the second quarter of this year, as it prepares to launch a Phase IIb trial of bexotegrast in the middle of the year. The team is hopeful that the results will help to further advance the development of this exciting new compound.
Funding a Promising Pipeline and a Powerful Platform
Monday’s public offering is an exciting step forward in the clinical trials of bexotegrast, a promising candidate for the treatment of primary sclerosing cholangitis. With data due to be released later this year, this offering can help propel the advancement of this potentially life-changing drug.
Pliant is investing in IPF hopeful and PLN-101095, an investigational selective inhibitor of αvβ8/αvβ1 integrin. This dual mode treatment targets both T cells and fibroblasts, making it a promising treatment option for solid tumors. The hope is that this innovative approach will lead to better outcomes for those suffering from this devastating disease.
Research has provided compelling evidence that PLN-101095’s αvβ8 action, when combined with PD-(L)1 therapeutics, could be an effective treatment option. This promising combination could offer a new and exciting approach to treating diseases.
Pliant is on the cutting edge of medical innovation with its Investigational New Drug application for PLN-101095, and is poised to begin a groundbreaking first-in-human trial in the second quarter of 2021. This milestone marks an exciting step forward in Pliant’s efforts to revolutionize medical treatments and push the boundaries of what’s possible.
Pliant Therapeutics is launching a public offering that will enable the further development of its integrin targeting platform. This comprehensive platform includes a library of over 10,000 annotated integrin-binding molecules to target and identify drivers of fibrotic diseases, an expression atlas, a screening assay platform, and a ligand imaging program. Additionally, biomarker assays will be made available to understand and diagnose the severity of these diseases.
The proceeds of the public offering will be used to fuel the company’s working capital, operating expenses, capital expenditures, and other general corporate functions. This injection of funds will enable the company to continue to grow, develop new products and services, and stay competitive in the market.